Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 2

Conditions

Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × gemcitabine-oxaliplatin regimen × Lymphoid × Clear all
NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated
56 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡